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Background: Iron deficiency anemia is highly prevalent in patients with chronic kidney disease and is often treated
with intravenous iron. There are few trials directly comparing the safety and efficacy of different intravenous iron
products.
Methods: This post-hoc analysis pooled data from 767 patients enrolled in two randomized, controlled, open-label
trials of similar design comparing the treatment of iron deficiency anemia with ferumoxytol and iron sucrose across
patients with all stages of renal function. One trial was conducted in adults with CKD either on or not on dialysis
and the second in adults with IDA of any underlying cause and a history of unsatisfactory oral iron therapy or in
whom oral iron could not be used who had normal to no worse than moderately impaired renal function. Patients
were categorized by chronic kidney disease stage (i.e., estimated glomerular filtration rate), and the primary efficacy
endpoint was the mean change in hemoglobin from Baseline to Week 5.
Results: The overall incidence of adverse events was numerically lower in ferumoxytol-treated patients compared
to those treated with iron sucrose (42.4 vs. 50.2 %, respectively); the incidence of treatment-related adverse events
was generally similar between the two treatment groups (13.6 vs. 16.0 %, respectively). Adverse events of Special
Interest (i.e., hypotension, hypersensitivity) occurred at lower rates in those treated with ferumoxytol compared to
those treated with iron sucrose (2.5 vs. 5.3 %, respectively). Overall, mean hemoglobin increased in both treatment
groups, regardless of degree of renal insufficiency, although greater increases were seen among those with less
severe kidney damage. Mean increases in hemoglobin from Baseline to Week 5 were significantly greater with
ferumoxytol than with iron sucrose treatment in the subgroup with an estimated glomerular filtration rate ≥90 mL/min
(Least Squares mean difference = 0.53 g/dL; p < 0.001). There were no other consistent, significant differences in
hemoglobin levels between treatment groups for the other chronic kidney disease categories except for isolated
instances favoring ferumoxytol.
Conclusions: The efficacy and safety of ferumoxytol is at least comparable to iron sucrose in patients with varying
degrees of renal function.
Trial registration: (CKD-201; ClinicalTrials.gov identifier: NCT01052779; registered 15 January, 2010), (IDA-302;
ClinicalTrials.gov identifier: NCT01114204; registered 29 April, 2010).
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Iron deficiency anemia (IDA) is the leading cause of
anemia worldwide [1]. In the United States, IDA affects
approximately 1 to 2 % of men and 2 to 5 % of women
[2]. IDA is particularly common in patients with chronic
kidney disease (CKD) [3–5].
Correction of the underlying cause of IDA and reple-
tion of depleted iron stores are fundamental approaches
to the treatment and management of IDA [6]. Intraven-
ous (IV) iron plays a major role in the treatment of IDA
across all degrees of renal function, and in particular for
those with CKD, including dialysis-dependent CKD pa-
tients, and non-CKD patients unable to tolerate oral iron
or in whom oral iron is either ineffective or contraindi-
cated. According to the 2012 Kidney Disease Improving
Global Outcomes clinical practice guidelines, a trial of
IV iron is recommended in all adult CKD dialysis pa-
tients with anemia not on iron or erythropoiesis-
stimulating agent therapy and in non-dialysis patients
with CKD after a failed trial of oral iron [7].
The efficacy of IV iron supplementation in the treat-
ment of IDA has been studied in patients with a variety
of underlying conditions, including CKD, abnormal uter-
ine bleeding, pregnancy, postpartum anemia, cancer, and
gastrointestinal (GI) disorders, including inflammatory
bowel disease and GI blood loss. However, few random-
ized head-to-head studies specifically comparing the
relative safety and efficacy of IV iron products have been
conducted [8–12].
Ferumoxytol, a colloidal iron oxide, is an IV iron
product approved for the treatment of IDA in adult pa-
tients with CKD in the US and Canada as Feraheme®
(ferumoxytol) Injection and, at the time of this analysis,
was marketed in the US as Feraheme and in the
European Union and Switzerland as Rienso® (ferumoxytol)
[13]. Ferumoxytol has been investigated for the broad
indication of IDA in those who have failed or who are
intolerant to oral iron therapy. Unlike most other IV
iron products, a full course of ferumoxytol therapy
(1.02 g) requires only two IV administrations of
510 mg, delivered between 3 and 8 days apart. Iron su-
crose (Venofer®) is approved in the US as an iron re-
placement product for the treatment of IDA in
patients with CKD. Iron sucrose is administered in
small doses as a slow IV injection or longer infusion
and requires the administration of multiple doses. At
the time of this publication, there were little data on
the efficacy and safety of iron replacement therapy in
patients with various stages of renal function. Thus,
the primary objective of this analysis was to provide a
deeper understanding of the comparative safety and ef-
ficacy of ferumoxytol and iron sucrose across all stages
of renal function, from normal kidney function to end-
stage CKD.Methods
Two recently completed clinical trials compared the ef-
ficacy and safety of ferumoxytol with iron sucrose for
the treatment of IDA in adults with CKD either on or
not on dialysis (CKD-201; ClinicalTrials.gov identifier:
NCT01052779), and in adults with IDA of any under-
lying cause and a history of unsatisfactory oral iron
therapy or in whom oral iron could not be used (IDA-
302; ClinicalTrials.gov identifier: NCT01114204). Here,
we report the pooled safety and efficacy results of these
two randomized, controlled studies with similar study
designs to better characterize the safety and efficacy of
these IV iron products across all stages of renal func-
tion, from normal kidney function to end-stage CKD,
as categorized by estimated glomerular filtration rate
(eGFR) levels of ≥90, 60 to <90, 30 to <60, 15 to <30,
and <15 mL/min.
This post-hoc analysis included pooled data from all
patients in the Intent-to-Treat (ITT) populations of
two randomized, open-label, controlled clinical trials
(CKD-201 and IDA-302) of similar design (N = 767).
Full details of the study designs and results for the
overall patient populations were presented separately in
the original two papers [14, 15]. Both studies were con-
ducted in accordance with the ethical principles of
Good Clinical Practice and in compliance with the
Declaration of Helsinki. The study protocols were
reviewed and approved by the institutional review
boards or ethics committees at each study site
(Additional file 1). Ethical approval for the current
study was not required, as it is a post-hoc analysis of
pooled data from two previously published clinical tri-
als. All patients provided written informed consent
prior to study entry.
The CKD-201 study included adults aged ≥18 years with
CKD on or not on hemodialysis. Patients were required to
have a serum hemoglobin (Hgb) <11.0 and ≥7 g/dL and a
transferrin saturation (TSAT) <30 % [14]. The IDA-302
study included patients who had various primary under-
lying conditions associated with IDA (e.g., abnormal uterine
bleeding, cancer, GI disorders, postpartum anemia, and
other conditions) with normal (eGFR >90 mL/min), mild
(eGFR of 60–90 mL/min), and moderate (eGFR of 30–
59 mL/min) decreased renal function, but excluded those
with severe (eGFR < 30 mL/min) kidney disease. Patients in
IDA-302 included adults aged ≥18 years with a Baseline
Hgb >7 to <10 g/dL and a TSAT <20 % who had either
failed oral iron therapy or were intolerant to oral iron [15].
There were a total of 162 patients from the CKD-201
study and 605 patients from the IDA-302 study. Overall,
486 patients received ferumoxytol and 281 received iron
sucrose. Both studies included a 14-day screening
period. Patients in the Ferumoxytol Treatment Group
received a 510-mg IV dose at the Baseline visit (Day 1)
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as a rapid IV injection of 17 mL at a rate not to exceed
1 mL/sec. Patients were observed weekly until the end
of the 5-week treatment period (Weeks 2–5). Patients
randomized to the Iron Sucrose Treatment Group re-
ceived a cumulative dose of 1 g as 10 IV doses of
100 mg (hemodialysis patients, CKD-201) within 3 weeks
or five IV doses of 200 mg on five non-consecutive days
over a 14-day period (non-dialysis CKD patients, CKD-
201; all patients, IDA-302). Iron Sucrose was given as
an infusion or slow injection. Infusions were given at
25 mg for the first 15 min; if no adverse events (AEs) oc-
curred, the remaining dose was given at a rate not ex-
ceeding 100 mg over 15 min. Slow injections were given
at 1 mL (20 mg) over 1–2 min; if no AEs occurred, the
remaining dose was given. Blood samples were collected
at Screening, Baseline, and weekly Visits 2 to 5 to assess
efficacy (Hgb, TSAT, other iron measures).Table 1 Demographic and baseline characteristics of pooled treatm
Ferumoxytol Treatment Group
Mean age, years (SD) 50.1 (15.75)
Mean weight, kg (SD) 70.9 (16.07)





American Indian/Alaskan Native 0 (0.0)
Asian 51 (10.5)
Black/African American 27 (5.6)





Not Hispanic/Latino 474 (97.5)
CKD stage, n (%)
Stage 1 (eGFR ≥90 mL/min) 280 (57.6)
Stage 2 (eGFR 60 to <90 mL/min) 104 (21.4)
Stage 3 (eGFR 30 to <60 mL/min) 41 (8.4)
Stage 4 (eGFR 15 to <30 mL/min) 23 (4.7)




ESA use, n (%) 45 (9.3)
ESA erythropoiesis-stimulating agent, eGFR estimated glomerular filtration rate, Hgb
aBaseline values obtained Day 1 prior to injection of study drugThe safety population included all randomized pa-
tients who had any exposure to study drug and was
based on actual treatment received. The ITT popula-
tion included any randomized patient who had any ex-
posure to study drug (IV ferumoxytol or IV iron
sucrose) and was based upon randomized treatment as-
signment. The safety and ITT populations were identi-
cal in this analysis.
The safety analysis included descriptive summaries of
overall AEs, serious AEs (SAEs), study drug-related AEs,
AEs resulting in study drug discontinuation, and AEs of
Special Interest (AESIs; predefined as moderate-to-severe
hypotension occurring on the day of dosing and
moderate-to-severe hypersensitivity reactions) and Com-
posite Cardiovascular AEs (predefined as nonfatal myocar-
dial infarction, heart failure, moderate-to-severe
hypertension, and hospitalization due to any cardiovascu-
lar event). The efficacy analysis focused on mean changeent groups (total study population - safety population)a
(n = 486) Iron Sucrose Treatment Group (n = 281) Total (N = 767)
52.8 (16.06) 51.1 (15.90)
76.0 (20.29) 72.8 (17.89)
166.5 (8.18) 166.0 (8.18)
199 (70.8) 582 (75.9)
82 (29.2) 185 (24.1)
1 (0.4) 1 (0.1)
18 (6.4) 69 (9.0)
16 (5.7) 43 (5.6)
1 (0.4) 3 (0.4)
234 (83.3) 624 (81.4)
11 (3.9) 27 (3.5)
13 (4.6) 25 (3.3)
268 (95.4) 742 (96.7)
126 (44.8) 406 (52.9)
59 (21.0) 163 (21.3)
33 (11.7) 74 (9.6)
20 (7.1) 43 (5.6)
42 (14.9) 80 (10.4)
1 (0.4) 1 (0.1)
36 70
40 (14.2) 85 (11.1)
hemoglobin, SD standard deviation
Fig. 1 Patient flow diagram. AE, adverse event
Table 2 Baseline laboratory values by CKD stage, mean (SD)













All stages 9.1 (1.04) (n = 486) 9.2 (1.11) (n = 280) 8.7 (12.93) (n = 486) 9.4 (12.40) (n = 280) 68.8 (170.04) (n = 481) 88.6 (184.48) (n = 279)
Stage 1 (eGFR
≥90 mL/min)
8.8 (0.95) (n = 280) 8.8 (0.98) (n = 126) 5.8 (11.25) (n = 280) 4.3 (5.21) (n = 126) 14.1 (39.76) (n = 276) 15.4 (53.11) (n = 125)
Stage 2 (eGFR 60
to <90 mL/min)
9.1 (1.0) (n = 104) 8.9 (0.89) (n = 59) 6.6 (5.7) (n = 104) 5.1 (3.47) (n = 59) 55.4 (138.26) (n = 103) 22.7 (80.21) (n = 59)
Stage 3 (eGFR 30
to <60 mL/min)
9.3 (0.86) (n = 41) 9.5 (0.88) (n = 33) 13.4 (18.31) (n = 41) 16.1 (22.18) (n = 33) 106.6 (168.37) (n = 41) 106.5 (157.15) (n = 33)
Stage 4 (eGFR 15
to <30 mL/min)
9.8 (0.84) (n = 23) 10.0 (0.76) (n = 20) 21.7 (19.41) (n = 23) 17.0 (6.49) (n = 20) 152.3 (123.03) (n = 23) 141.4 (158.16) (n = 20)
Stage 5 (eGFR
<15 mL/min)
10.2 (1.09) (n = 38) 10.2 (1.10) (n = 42) 22.3 (12.91) (n = 38) 21.7 (14.76) (n = 42) 411.3 (348.97) (n = 38) 359.7 (287.65) (n = 42)
eGFR estimated glomerular filtration rate, Hgb hemoglobin, SD standard deviation, TSAT transferrin saturation
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efficacy endpoint in both individual studies. The treatment
difference in the Hgb change was analyzed using an ana-
lysis of covariance model adjusting for Baseline Hgb, pri-
mary underlying conditions, and dialysis status.Results
Baseline characteristics and patient disposition
The demographic and baseline characteristics for the
Ferumoxytol and Iron Sucrose Treatment Groups were
comparable (Table 1). The majority of the study popula-
tion was comprised of women (75.9 %). The mean (±
standard deviation [SD]) age was 51.1 ± 15.9 years and
most patients were white (81.4 %). The following differ-
ences were noted in the characteristics between the two
study populations: The mean age of patients in CKD-
201 was 14.4 years greater and the mean weight was
16.3 kg greater. More patients in CKD-201 were receiv-
ing treatment with an erythropoiesis-stimulating agent
than those from IDA-302 (52 % of patients in CKD-201




All AEs 206 (42.4)
Treatment-related AEs 66 (13.6)
SAEs 24 (4.9)
Treatment-related SAEs 3 (0.6)
AEs of Special Interesta 12 (2.5)
Cardiovascular AEsb 6 (1.2)
AEs resulting in temporary discontinuation of study drug 3 (0.6)
AEs resulting in permanent discontinuation of study drug 7 (1.4)
AEs resulting in study discontinuation 4 (0.8)
Death 1 (0.2)





Peripheral edema 5 (1.0)
Urinary tract infection 5 (1.0)




Data are presented as n (%). AE: adverse event; SAE: serious adverse event
aIncludes hypotension and hypersensitivity
bIncludes myocardial infarction, heart failure, moderate to severe hypertension, andpercentage of patients from IDA-302 had more severe
anemia on study entry with 33 % having a Baseline Hgb
value ≤8.5 g/dL, while only 13 % of patients from CKD-
201 had a Baseline Hgb ≤9 g/dL. Approximately one-half
of the study population (52.9 %) had normal renal function
(eGFR >90 mL/min), and the distribution of patients classi-
fied by eGFR category (i.e., eGFR ≥90, 60 to <90, 30 to <60,
15 to <30, and <15 mL/min) is summarized in Table 1.
Mean Baseline values for iron parameters by Baseline CKD
stage are summarized in Table 2, with an overall Baseline
mean Hgb of 9.1 (±1.04) g/dL in the Ferumoxytol Treat-
ment Group and 9.2 (±1.11) g/dL in the Iron Sucrose treat-
ment group. Patient disposition is illustrated in Fig. 1.
Approximately 94 % of patients in each treatment
group completed the study. The mean total cumulative
doses of IV iron (mg) in the Ferumoxytol and Iron Su-
crose Treatment Groups were comparable (1005.0 ±
85.61 and 966.0 ± 142.6 mg, respectively).
Safety
The pooled safety population (i.e., ITT population) in-




Group (n = 281)
Total (N = 767)
141 (50.2) 347 (45.2)
45 (16.0) 111 (14.5)
11 (3.9) 35 (4.6)
1 (0.4) 4 (0.5)
15 (5.3) 27 (3.5)
3 (1.1) 9 (1.2)
4 (1.4) 7 (0.9)
9 (3.2) 16 (2.1)
6 (2.1) 10 (1.3)
0 (0.0) 1 (0.1)
up by decreasing incidence in the Ferumoxytol Treatment Group
13 (4.6) 35 (4.6)
10 (3.6) 27 (3.5)
5 (1.5) 15 (2.0)
14 (5.0) 24 (3.1)
8 (2.8) 13 (1.7)
9 (3.2) 14 (1.8)
6 (2.1) 11 (1.4)
6 (2.1) 10 (1.3)
10 (3.6) 13 (1.7)
7 (2.5) 9 (1.2)
hospitalization due to any cardiovascular cause
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The overall incidence of all AEs was 42.4 % in the
Ferumoxytol Treatment Group and 50.2 % in the Iron
Sucrose Treatment Group. The incidence of
treatment-related AEs was similar (13.6 and 16.0 % for
ferumoxytol and iron sucrose, respectively; Table 3).
The most frequent AEs were headache (4.5 %) and
nausea (3.5 %) in the Ferumoxytol Treatment Group,
and dysgeusia (5.0 %) and headache (4.6 %) in the Iron
Sucrose Treatment Group (Table 3). Overall AEs and
treatment-related AEs occurring within 24 h of each
dose are summarized in Fig. 2. Frequencies of AEs
were generally similar between the Ferumoxytol and
Iron Sucrose Treatment Groups during Weeks 1 and 2,
although the Iron Sucrose Treatment Group continued to
experience AEs with subsequent administrations.
Discontinuation due to AEs occurred at comparable
rates in the Ferumoxytol (0.8 %) and Iron Sucrose
(2.1 %) Treatment Groups. Similarly, the proportion ofFig. 2 Adverse events (AEs) within 24 h post-dosing. a All
treatment-emergent AEs by treatment and dose number. b All
treatment-related AEs by treatment and dose number. Pts, patientspatients experiencing AESIs (i.e., hypotension and hyper-
sensitivity) was comparable between treatment groups
(ferumoxytol, 2.5 %; iron sucrose, 5.3 %; Table 3). Five of
the AESIs in the Iron Sucrose Treatment Group oc-
curred at Weeks 3 through 10 (i.e., after all ferumoxytol
administrations had been completed). One patient death
occurred in the Ferumoxytol Treatment Group. The pa-
tient had a pancreatic tumor causing duodenal obstruc-
tion and died postoperatively; this was considered
unrelated by the Investigator. Composite Cardiovascular
AEs occurred at a similar incidence in both treatment
groups (ferumoxytol, 1.2 %; iron sucrose, 1.1 %). Simi-
larly, rates of SAEs and treatment-related SAEs were
comparable between treatment groups (ferumoxytol, 4.9
and 0.6 %; iron sucrose 3.9 and 0.4 %, respectively). Four
patients (0.5 %) experienced an SAE within 24 h of the
first dose of IV iron (ferumoxytol, n = 1 [0.2 %]; iron su-
crose, n = 3 [1.1 %]). SAEs occurring within 24 h of the
first dose of IV iron were considered treatment-related
in one patient in each group (ferumoxytol, 0.2 %-moder-
ate intensity anaphylactic-type reaction that resolved on
the day of dosing; iron sucrose, 0.4 %-moderate intensity
hypotension treated with volume and Trendelenburg
positioning).
Efficacy
Hgb levels increased from Baseline until the end of the
study in both treatment groups; Fig. 3 summarizes
mean Hgb levels over time by CKD stage. For patients
with an eGFR ≥90 mL/min (normal renal function),
mean (± SD) Hgb increased from 8.8 (±0.95) mg/dL at
Baseline to 12.1 (±1.3) mg/dL at Week 5 (a change of
3.3 g/dL) in the Ferumoxytol Treatment Group, while
mean Hgb increased from 8.8 (±0.98) mg/dL to 11.6
(±1.33) mg/dL (a change of 2.8 g/dL) for those in the
Iron Sucrose Treatment Group. For patients with nor-
mal renal function, ferumoxytol treatment resulted in
significantly greater increases in mean Hgb levels com-
pared with iron sucrose treatment at Weeks 2, 3, 4, and
5 (p < 0.001 vs. iron sucrose for all; Fig. 3a). Least
Squares (LS) mean treatment differences between the
Ferumoxytol and Iron Sucrose Treatment Groups for
Hgb levels ranged from 0.50 to 0.76 g/dL. Mean Hgb
values over time for the other CKD categories are illus-
trated in Fig. 3b–e. Ferumoxytol-treated patients with
eGFRs of 60 to <90 mL/min and <15 mL/min at Week
2 also had a significantly greater increase in Hgb levels
compared with iron sucrose-treated patients (p = 0.009
and p = 0.012, respectively, vs. iron sucrose); there were
no significant treatment differences in Hgb levels be-
tween treatment groups in the other categories of renal
function (Fig. 3b).
Mean Baseline TSAT increased with declining renal
function (Table 2). Treatment with both ferumoxytol
Fig. 3 Mean hemoglobin (Hgb) levels across renal functions. a eGFR ≥90 mL/min; (b) eGFR 60 to <90 mL/min; (c) eGFR 30 to <60 mL/min; (d)
eGFR 15 to <30 mL/min; and (e) eGFR <15 mL/min at Weeks 2, 3, 4, and 5 in patients receiving ferumoxytol or iron sucrose therapy (Intent-to-
Treat population). eGFR, estimated glomerular filtration rate
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values over the 5-week study period (Table 4). LS mean
increases in TSAT from Baseline to Week 5 were signifi-
cantly greater for those receiving ferumoxytol compared
with those receiving iron sucrose for the eGFR category
of 60 to <90 mL/min (15.9 vs. 11.3 %; p = 0.001). There
were no significant differences between Ferumoxytol
and Iron Sucrose Treatment Groups at Week 5 for any
of the other CKD categories.
Low serum ferritin is a marker for IDA, but an ele-
vated serum ferritin can be a marker of either increased
iron levels or inflammation, the latter of which can
mask the presence of IDA [7]. Overall, mean Baselinevalues for ferritin levels in the Ferumoxytol and Iron
Sucrose Treatment Groups were similar with increasing
Baseline ferritin levels with declining renal function
(Table 2). As for other iron parameters, treatment with
either ferumoxytol or iron sucrose was associated with
increased ferritin levels over time in all eGFR categories
(Table 4).
Discussion
The current analysis pooled data from two random-
ized, controlled clinical studies of IV iron treatment in
adults with IDA, which provided the opportunity to
more thoroughly analyze a larger number of patients
Table 4 Mean change in TSAT and serum ferritin over time by CKD stage









Stage 1 (eGFR ≥90 mL/min) (n = 280) (n = 126) (n = 280) (n = 126)
Baseline 5.8 (11.25) 4.3 (5.21) 14.1 (39.76) 15.4 (53.11)
Week 2 26.1 (19.59) 15.8 (11.90) 291.1 (192.69) 172.5 (245.93)
Week 3 24.1 (11.54) 19.8 (15.38) 179.7 (157.02) 157.3 (211.08)
Week 4 22.7 (10.95) 19.2 (13.81) 123.7 (124.20) 124.0 (211.93)
Week 5 22.9 (21.75) 19.1 (14.77) 98.3 (118.96) 96.4 (185.27)
Stage 2 (eGFR 60 to <90 mL/
min)
(n = 104) (n = 59) (n = 104) (n = 59)
Baseline 6.6 (5.7) 5.1 (3.47) 55.4 (138.26) 22.7 (80.21)
Week 2 26.2 (11.41) 25.8 (51.56) 442.0 (398.63) 215.0 (226.93)
Week 3 24.3 (10.39) 17.2 (7.81) 325.6 (385.93) 196.6 (212.70)
Week 4 23.9 (11.17) 18.9 (12.46) 277.9 (394.82) 166.2 (254.32)
Week 5 22.5 (10.35) 16.5 (6.66) 247.2 (471.24) 127.5 (214.99)
Stage 3 (eGFR 30 to <60 mL/
min)
(n = 41) (n = 33) (n = 41) (n = 33)
Baseline 13.4 (18.31) 16.1 (22.18) 106.6 (168.37) 106.5 (157.15)
Week 2 26.6 (13.27) 21.8 (22.81) 629.3 (507.21) 338.6 (296.76)
Week 3 25.0 (11.45) 18.9 (8.16) 518.1 (425.74) 373.0 (321.68)
Week 4 23.2 (11.01) 19.2 (7.78) 452.5 (443.14) 314.8 (284.35)
Week 5 23.1 (12.15) 19.4 (7.86) 426.0 (433.68) 312.0 (284.41)
Stage 4 (eGFR 15 to <30 mL/
min)
(n = 23) (n = 20) (n = 23) (n = 20)
Baseline 21.7 (19.41) 17.0 (6.49) 152.3 (123.03) 141.4 (158.16)
Week 2 30.6 (9.71) 24.3 (7.14) 720.7 (280.38) 520.2 (244.56)
Week 3 28.6 (13.22) 24.0 (5.85) 632.8 (324.78) 529.6 (244.92)
Week 4 32.2 (15.81) 25.7 (7.18) 552.4 (327.53) 440.5 (228.45)
Week 5 26.3 (6.34) 23.1 (5.79) 514.6 (285.12) 407.0 (231.30)
Stage 5 (eGFR <15 mL/min) (n = 38) (n = 42) (n = 38) (n = 42)
Baseline 22.3 (12.91) 21.7 (14.76) 411.3 (348.97) 359.7 (287.65)
Week 2 34.6 (16.18) 25.4 (12.87) 915.8 (372.92) 603.4 (338.87)
Week 3 32.2 (12.81) 24.7 (7.44) 959.0 (605.92) 675.2 (339.54)
Week 4 30.4 (12.57) 27.7 (13.27) 831.7 (452.94) 682.2 (391.21)
Week 5 28.7 (8.82) 27.9 (15.80) 788.4 (427.21) 618.9 (355.47)
CKD chronic kidney disease, GFR glomerular filtration rate, SD standard deviation, TSAT transferrin saturation
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allowed for a comparative analysis of the Hgb re-
sponse to IV iron treatment based on underlying renal
function. Across all stages of renal function—from
normal to end-stage CKD—the comparison of the
safety and efficacy of ferumoxytol versus iron sucrose
treatment demonstrated consistent findings. Overall,
the incidences of all AEs were numerically lower in
the Ferumoxytol Treatment Group compared to those
treated with iron sucrose. This may be related to the
risk of AEs associated with each instance of an IVadministration, as suggested by the continued occur-
rence of AEs (including AESIs) after each dose in pa-
tients in the Iron Sucrose Treatment Group who
received up to 10 individual doses. The frequencies of
drug-related AEs and AE-related treatment discontin-
uations were slightly lower in the Ferumoxytol Treat-
ment Group compared with the Iron Sucrose
Treatment Group, while SAEs and treatment-related
SAEs were slightly higher with ferumoxytol than iron
sucrose. It is important to emphasize that, given the
low overall rates, no statistical comparisons were
Strauss et al. BMC Hematology  (2016) 16:20 Page 9 of 10appropriate. Overall, both agents had a comparable
rate of SAEs, treatment-related SAEs, and cardiovas-
cular AEs, and no new safety signals were identified.
These results are consistent with those observed in
the original Phase 3 studies [14, 15].
Hgb levels were increased in both the Ferumoxytol
and Iron Sucrose Treatment Groups at the end of the
study. Patients in all of the CKD categories were shown
to benefit from iron therapy, although those with the
most severe renal dysfunction achieved somewhat less
of an Hgb response. Compared with iron sucrose, feru-
moxytol treatment resulted in a significantly greater in-
crease in Hgb at all time points assessed in those with
an eGFR ≥90 mL/min. Statistically significant differ-
ences between treatment groups were not observed for
patients with decreased levels of renal function for the
majority of time points.
A low serum ferritin is indicative of iron deficiency,
and elevated levels may be indicative of increased iron
stores or iron overload. However, since ferritin is also an
acute phase reactant, it is also a surrogate marker for in-
flammation and may be elevated due to chronic inflam-
mation even in the presence of IDA [7]. Thus, while
ferritin levels can be used to assess iron levels and the
efficacy of active therapies, they must be used with cau-
tion in patients with CKD, especially with those on dia-
lysis [7]. In this study, Baseline levels were increased in
patients with reduced renal function. Treatment with ei-
ther ferumoxytol or iron sucrose was shown to produce
increases in serum ferritin across all CKD categories.
The increases in TSAT levels were significantly greater
with ferumoxytol than with iron sucrose in all CKD cat-
egories as early as Week 2 and/or 3 following the start
of treatment, indicating that ferumoxytol is associated
with a faster replenishment of iron stores available for
erythropoiesis.
A limitation of this study is the retrospective nature of
the analysis. Another limitation of this pooled analysis is
that data were pooled across different populations. In
particular, patients in CKD-201 were older and heavier
compared with those from study IDA-302. Patients in
CKD-201 were also less likely to have more severe
anemia than those in IDA-302, most likely because
CKD patients routinely receive aggressive therapy for
anemia (e.g., iron therapy, erythropoiesis-stimulating
agents).
Conclusions
This pooled analysis of two randomized, controlled
clinical trials of IV iron treatment provides the oppor-
tunity to compare the safety and efficacy of two IV iron
replacement products in a large population of patients
with IDA and varying degrees of renal function. Over-
all, the efficacy of ferumoxytol was shown to becomparable, and at times greater, to that of iron su-
crose for increasing Hgb across the spectrum of renal
function, from normal to patients with CKD on dialysis.
Overall, mean Hgb increased in both treatment groups,
regardless of degree of renal insufficiency. Although pa-
tients with worse renal function did not respond as well
to IV iron therapy with either drug compared to those
with normal renal function, patients in all CKD cat-
egories experienced improved iron parameters. In this
pooled analysis, both ferumoxytol and iron sucrose
were shown to have comparable safety profiles consist-
ent with those observed in the original studies.
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